Balloon Catheters Market

The market for Balloon Catheters was estimated at $3.8 billion in 2025; it is anticipated to increase to $5.0 billion by 2030, with projections indicating growth to around $6.6 billion by 2035.

Report ID:DS1801408

Author:Debadatta Patel - Senior Consultant

Published Date:July 2025

Datatree

Life Science

Medical Device

Balloon Catheters

Customization Available

Balloon Catheters - 2025-2035

Market Outlook
Market Key Insights
Growth Opportunity
Market Dynamics
Application
Recent Development
Impact Analysis

Report Summary

Market Data

Methodology

Table of Contents

Report Summary

Market Data

Methodology

Table of Contents

Global Balloon Catheters Market Outlook

Revenue, 2025

$3.8B

Forecast, 2035

$6.6B

CAGR, 2026 - 2035

5.7%

The Balloon Catheters industry revenue is expected to be around $3.8 billion in 2026 and expected to showcase growth with 5.7% CAGR between 2026 and 2035. The high proportion of balloon catheter use in conjunction with other cardiology and urology treatments underlines the importance of balloon catheters in the interventional tools of these fields. This is particularly true in the cases where such treatments are used together which today happens in 73.1% of cases. This can be explained by the fact that, balloon catheters are used in treatments of urological and cardiology problems which are rising. Also these catheters are used in treatments that are minimally invasive, and it is in these treatments that many doctors now treat their patients. Compliant balloon catheters, generating a revenue of approximately $1.75 billion in 2025, hold a dominant position in the market due to their ability to provide a suitable balance between flexibility and pressure in catheters used for angioplasty and other cardiovascular purposes. Technological advancements, miniaturisation of devices, polymer engineering and the improved compatibility with imaging tools are further enhancing the utility of these technologies. These developments are especially relevant in complex cases, in treatment of high risk patients and out patient cardiac procedures.

These catheters, which are designed for use in the medical field, are long thin tubes with an inflatable part at the end. This part can be positioned precisely and inflated to allow a blood vessel to widen, to put a stent in place or to deliver a drug directly to a specific region. These devices have a number of characteristics including semi compliant and non compliant balloons, the ability to handle high pressure without bursting, markers which show up on X rays, a coating which reduces friction and compatibility with medical imaging equipment. The uses of these devices range from angioplasty in coronary and peripheral arteries to the treatment of heart and artery disease via coronary catheters, drug coated catheters and other devices. Urology is also catered to through the use of catheters and balloon catheters in the treatment of stones within the urinary tract. Developments such as ultra low profile catheter shafts, balloon catheters specifically designed for peripheral vascular procedures, integration with radial access techniques and targeted drug delivery systems are causing a growing need for catheters in a variety of medical settings.

Balloon Catheters market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035 — Balloon Catheters Market Outlook

Market Key Insights

The Balloon Catheters market is projected to grow from $3.8 billion in 2025 to $6.6 billion in 2035. This represents a CAGR of 5.7%, reflecting rising demand across Angioplasty, Stent Placement, and Urological Procedures.
The medical guidewire industry is dominated by seven leading corporations, Boston Scientific and Medtronic, these two possessing the biggest share of the market.
The US and Germany will likely dominate the balloon catheters market, with the countries predicted to register a growth rate of 3.7% to 5.5% from 2025 and 2030.
The countries with the greatest expected growth rates will be the emerging markets of Brazil, India and South Africa, with a compound annual growth rate between 6.6% and 7.9%.
Investors expect that this market will experience technological advancements which could aid its growth in future years due to current low growth rates of 5.7%. Investors will however provide $137 million by the year 2030.
During the forecast period, the balloon catheter market is anticipated to increase by $2.8 billion. Market expansion in the cardiology and gastroenterology sector is anticipated.
With
rising prevalence of cardiovascular diseases and increasing adoption of minimally invasive procedures, and
Technological Advancements in Drug-Coated and High-Performance Balloon Catheters Improving Outcomes, Balloon Catheters market to expand 74% between 2025 and 2035.

Balloon Catheters - Country Share Analysis

Opportunities in the Balloon Catheters

Comprehensive stroke facilities in China and India are being developed rapidly. This is also resulting in an increased requirement for balloon catheters that are suited to neurovascular treatment. These catheters are particularly used for treating delicate blood vessels in the brain. Minimal invasive treatments, including coiling assistance, vessel remodelling and distal access, benefit from low profile and ultra compliant balloon catheters. By 2030, it is estimated that the global balloon catheter market will reach $1.11 billion and $0.84 billion in 2025. This growth is predicted to be at a compound annual growth rate of 5.7%. The neurointerventional applications in the Asia Pacific region are set to be faster than the rest of the endovascular therapy market.

Growth Opportunities in North America and Asia-Pacific

In cardiology across North America, balloon catheters have experienced the most significant increase in usage. This is particularly true of balloon catheters used in angioplasty and drug coated balloons. They are used in complex cardiology procedures and also in PCI that is outpatient. The greatest opportunities in the business can be found in products and services which are of a high standard and are clinically different. These devices are used for the hearts main artery and the arteries in the limbs. They are also integrated with other products that help doctors plan treatments using images. Another region of opportunity is a pricing system that ensures a lower cost to the health service if patients are discharged more quickly. High levels of competition are prevalent in the interventional cardiology devices market with multinational companies being challenged by smaller innovative companies and also by private label products. Consequently, interventional cardiology devices companies need to have access to robust clinical data, novel coating technologies and also relationships with hospitals and purchasing groups. Key factors driving demand in this market include the growing number of individuals with a high incidence of urological conditions, the reimbursement of endoscopic treatments by private insurance, and an increase in the use of balloon catheters for the treatment of kidney stones and benign prostatic hyperplasia.

Asia Pacific market for balloon catheters will benefit significantly from the large expansion of cath labs in this region. As such cardiology will be the major driver of this growth, but urology and gastroenterology is experiencing rapid growth. These latter are secondary applications of balloon catheters. The most promising markets are for mid priced angioplasty balloon catheters that are reliable and tailored to local blood vessel anatomies, for drug coated balloon catheters which are cost efficient and used in high volume public hospitals, and training led expansion into developing countries where clinical skills and procedures are still being established. As the market evolves, it is being increasingly influenced by agile manufacturers that are local to the region. These manufacturers adapt their production to the local market and are extremely aggressive in the bidding process. This is making it difficult for the imported brands to compete as they must now differentiate themselves by providing high quality products. The demand for balloon catheters is driven by increasing incidence of heart conditions and diabetes, coupled with growing government investment in interventional cardiology equipment, more people having health insurance and patients increasing preference for minimally invasive surgery. This will create a demand for balloon catheters in both big and smaller cities.

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Cardiovascular Diseases and Increasing Adoption of Minimally Invasive Procedures

The growing global burden of cardiovascular diseases, including coronary artery disease and peripheral artery disease, is also a key driver for the balloon catheter market. As the incidence of atherosclerosis and related conditions rises due to aging populations, sedentary lifestyles, and diabetes prevalence, the demand for effective interventional solutions like angioplasty increases. Simultaneously, there is also a marked shift toward minimally invasive procedures over open surgeries, as these approaches reduce patient recovery time, lower complication risks, and shorten hospital stays. Balloon catheters, including high‑pressure and drug‑coated variants, are also integral to these procedures, enabling precise vessel dilation and stent placement. Together, the rising cardiovascular disease incidence and preference for minimally invasive interventions are also expanding procedure volumes, driving demand for innovative balloon catheter designs and high‑performance materials.

Innovation in balloon catheter technology is also accelerating market growth by enhancing procedural success and patient safety. Drug-coated balloon catheters release antiproliferative agents that prevent restenosis, reducing repeat interventions, while high-performance materials improve trackability, flexibility, and deliverability in complex vascular anatomies. also advances such as ultra-thin walls, dual-lumen designs, and improved radiopacity enable clinicians to navigate tortuous vessels and precisely position stents or dilate strictures. Adoption of these advanced devices is also increasing in cardiac, peripheral, and urological procedures, supporting higher efficacy, reduced complications, and growing confidence among interventional specialists.

Restraint: High Procedure Costs and Reimbursement Constraints Limit Balloon Catheter Adoption

The high cost of balloon catheter procedures and inconsistent reimbursement policies are significant restraints on market growth. Advanced devices such as drug‑coated balloons and specialty urological catheters often carry premium pricing, limiting their use in cost‑sensitive healthcare systems. For example, lack of adequate reimbursement for drug‑coated balloon angioplasty can discourage hospitals from adopting these technologies, reducing procedure volumes and negatively impacting overall market revenue and access, especially in emerging regions.

Opportunity: Europe's ageing PAD population and day-care endovascular centers boosting semi-compliant peripheral balloon catheters and US structural heart and complex coronary interventions accelerating adoption of high-pressure non-compliant balloon catheters

The requirement for balloon catheters for treating peripheral artery disease is increasing in Europe due to an ageing population that is now more frequently seeking medical help. The unexploited potential of specially designed angioplasty catheters with drug coatings and semi compliance, intended for below the knee usage, and in prone to restenosis arteries, remains to be investigated. The global market for semi compliant balloon catheters generated revenue of $1.75 billion in the year 2025. It is predicted that this will rise to $2.26 billion by the year 2030. This is a growth rate of 5.3% per annum. The growth of the peripheral angioplasty sector is the key factor in the rapid increase in demand for interventional cardiology devices used in minimally invasive endovascular therapy worldwide.

Increasing need for accurate lesion preparation in the United States is driving demand for balloon catheters which are non compliant. This is due to the recent rapid expansion of coronary intervention for complex cases, mitral repair, and TAVR. Medical institutions are searching for high pressure angioplasty catheters that allow for optimal stent deployment in calcified arterial plaque with a reduced incidence of geographic miss. By the year 2025, it is expected that the global balloon catheters market will be worth $1.23 billion, rising to $1.67 billion by 2030 at a compound annual growth rate of 6.26%. Balloon catheters are used to treat complex coronary and structural heart problems. They represent a prime growth opportunity within the catheter based therapy market.

Challenge: Risk of Clinical Complications and Preference for Alternative Technologies Suppress Demand

Concerns about procedural complications and competition from alternative interventional technologies restrict balloon catheter demand. Risks such as vessel dissection, restenosis, or perforation may lead clinicians to choose stents, atherectomy devices, or cutting balloons instead, influencing treatment patterns. For instance, clinicians may favor drug‑eluting stents over plain balloon angioplasty in complex lesions, shifting revenue away from traditional balloon catheters and altering market dynamics toward multifunctional or hybrid devices.

Supply Chain Landscape

Polymer Components Sourcing

Zeus Industrial ProductsLubrizol Life ScienceRaumedic

Balloon Catheters Manufacturing

Boston Scientific CorporationMedtronic plcAbbott Laboratories

Angioplasty Catheters Distribution

Cardinal HealthMedline IndustriesOwens & Minor

Clinical End Users

HospitalsCardiac Catheterization LabsAmbulatory Surgical Centers

Polymer Components Sourcing

Zeus Industrial ProductsLubrizol Life ScienceRaumedic

Balloon Catheters Manufacturing

Boston Scientific CorporationMedtronic plcAbbott Laboratories

Angioplasty Catheters Distribution

Cardinal HealthMedline IndustriesOwens & Minor

Clinical End Users

HospitalsCardiac Catheterization LabsAmbulatory Surgical Centers

Balloon Catheters - Supply Chain

Use Cases of Balloon Catheters in Angioplasty & Stent Placement

Angioplasty : Balloon catheters are primarily used in angioplasty to widen narrowed or blocked blood vessels, restoring blood flow in coronary or peripheral arteries. Percutaneous transluminal balloon catheters compress plaque and expand the vessel lumen, reducing ischemia and angina symptoms. Their advantages include minimally invasive delivery, precise dilation, and rapid recovery compared with open surgery. Leading market players such as Boston Scientific, Medtronic, and Abbott are distinguished by advanced balloon materials, high‑pressure performance and strong clinical support, strengthening their positions in interventional cardiology.

Stent Placement : In stent placement procedures, balloon catheters serve as delivery systems to expand and seat stents in target vessels. Balloon‑expandable stent catheters ensure controlled deployment of metal scaffolds that maintain vessel patency after dilation. These catheters offer accuracy and reliability critical in coronary and peripheral artery stenting. Top companies including Boston Scientific, Terumo, and Cook Medical compete with innovative balloon designs and integrated stent systems, driving procedural efficiency and broad adoption across cardiac care facilities.

Urological Procedures : Balloon catheters are widely used in urology to treat strictures and obstructions in urethral or ureteral pathways. Urological dilation balloon catheters gently expand constricted areas caused by trauma, disease or post‑surgical scarring, improving urine flow and patient comfort. Advantages include targeted treatment, reduced tissue damage and low complication rates compared with surgical alternatives. Key players such as Cook Medical, Bard (BD), and Coloplast lead with specialized urology product portfolios, strong distribution channels and clinician training programs that support effective procedural outcomes.

Recent Developments

Recent developments in balloon catheters highlight increasing adoption of drug‑coated balloons and high‑pressure angioplasty balloons to improve outcomes in coronary and peripheral interventions. A key market trend is integration of advanced materials and radiopaque markers that enhance deliverability and procedural precision. Growth in minimally invasive vascular surgery and rising incidence of cardiovascular disease are driving demand, while regulatory emphasis on safety and efficacy continues shaping product design and clinical adoption across interventional cardiology and urology.

March 2024 : Boston Scientific’s AGENT paclitaxel drug‑coated balloon catheter secured FDA approval for treating coronary in‑stent restenosis (ISR), offering clinicians a novel coronary balloon option that delivers therapeutic drug doses to reduce repeat restenosis and improve long‑term outcomes in interventional cardiology.

June 2024 : Medtronic released the NC Euphora™ rapid exchange noncompliant balloon catheter, designed for controlled high‑pressure dilation and improved deliverability during percutaneous transluminal coronary angioplasty, enhancing procedural precision in complex lesions.

Impact of Industry Transitions on the Balloon Catheters Market

As a core segment of the Medical Device industry, the Balloon Catheters market develops in line with broader industry shifts. Over recent years, transitions such as Technological Advancements and Regulatory Changes have redefined priorities across the Medical Device sector, influencing how the Balloon Catheters market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

Technological Advancements

By the year 2030, an investment of $137 million is forecasted to be made by balloon catheter manufacturers, responding to the 5.7% annual growth rate of this industry. Technological advancements in this region are causing the market to shift from small improvements to a new phase. Key research region's will include drug eluting balloons for coronary and peripheral artery interventions as well as advanced angioplasty balloon materials which enhance flexibility, improve trackability and enhance biocompatibility. With new technology, the goal is to lower the likelihood of restenosis, carry out the procedures faster and bring about better long term outcomes. As such, balloon catheters are a key part of many medical treatments which are minimally invasive. This trend of manufacturers focusing more on the development of advanced interventional cardiology devices than standard products will allow the use of balloon catheters in a wider range of treatments, help manufacturers charge more for these devices and will increase the growth rate of the balloon catheters market.

Regulatory Changes

Regulatory changes have significantly shaped the balloon catheter industry, with agencies such as the FDA and the European Medicines Agency enforcing stringent safety and efficacy standards. Manufacturers must now demonstrate rigorous clinical data, quality control, and post-market surveillance before devices gain approval. This shift has encouraged innovation in high-performance materials, drug-coated technologies, and precision delivery systems to meet regulatory benchmarks. Associated industries, including medical device manufacturing, contract research organizations, and hospital procurement, have adapted by investing in compliant production processes, clinical trial management, and staff training. For example, device makers now collaborate closely with hospitals to provide evidence-based usage guidelines, ensuring patient safety while supporting adoption of advanced balloon catheters in angioplasty, stent placement, and urological procedures. This regulatory-driven transition promotes both product reliability and trust among healthcare providers.